Press Releases

6/23/2009 Javelin Pharmaceuticals Completes Open Label Safety Study of Dyloject(TM) -	10.4 KB
6/15/2009 New Study Shows Javelin Pharmaceutical's DylojectTM Well-Tolerated in High-Risk Patients with Impaired Renal and Hepatic Function	9.4 KB
5/7/2009 Javelin Pharmaceuticals, Inc. Reports First Quarter 2009 Results and Corporate Highlights	14.0 KB
5/4/2009 Javelin Pharmaceuticals to Announce First Quarter 2009 Financial Results	8.3 KB
3/12/2009 Javelin Pharmaceuticals Reports Fiscal Results for the Year Ended 2008	14.1 KB
3/5/2009 Javelin Pharmaceuticals Quarterly Conference Call Invitation	8.3 KB
1/15/2009 Javelin Pharmaceuticals Signs $71 million European Commercialization Partnership for Dyloject(R)	10.0 KB
1/8/2009 Javelin Pharmaceuticals CEO Martin J. Driscoll to Present at J.P. Morgan's 27th Annual Healthcare Conference	8.1 KB
12/9/2008 Dyloject(TM) Significantly Reduces Moderate-to-Severe Pain in Pivotal Phase 3 Orthopedic Surgical Trial	12.0 KB
11/14/2008 Javelin Pharmaceuticals Announces 15 Percent Reduction in Workforce	8.7 KB
11/10/2008 Javelin Pharmaceuticals, Inc. Reports Third Quarter 2008 Results and Corporate Highlights	11.7 KB
11/6/2008 Javelin Pharmaceuticals to Review Third Quarter 2008 Financial Results	7.7 KB
10/20/2008 Javelin Pharmaceuticals Appoints Dr. Eric Lang Vice President of Clinical Research	10.1 KB
9/22/2008 Javelin Enrolls First Patient in an Open Label Safety Study of Dyloject(TM)	10.6 KB
9/17/2008 Javelin Pharmaceuticals to Present at the 2008 UBS Global Life Sciences Conference	8.2 KB
9/16/2008 Javelin Pharmaceuticals Completes Patient Enrollment for Second of two Pivotal Phase 3 Studies of Dyloject(TM)	9.8 KB
8/26/2008 Javelin Pharmaceuticals CEO to Provide Corporate Overview at the BioCentury NewsMakers Conference	8.0 KB
8/21/2008 Javelin Presents Successful Pivotal Phase 3 Secondary Clinical Results for Dyloject(TM) at the 12th World Congress on Pain	10.6 KB
8/12/2008 Javelin Presents PMI-150 (Intranasal Ketamine) Data at Premier Department of Defense Scientific Meeting	11.9 KB
8/11/2008 Javelin Pharmaceuticals, Inc. to Present at 28th Annual Canaccord Adams Global Growth Conference in Boston	9.1 KB
Showing 1-20 of 131 releases Page: 1 2 3 4 5 6 7  See Next 20

CONTACT US   JOIN US   SITE MAP
© 2009 Javelin Pharmaceuticals,Inc. / Intrac,Inc. / IDDS,Inc. All rights reserved. All other trademarks are the properties of their respective owners. Reproduction in whole or in part in any form or medium without express written permission of Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. is prohibited.